Dearborn Partners’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.18M | Hold |
21,392
| – | – | 0.06% | 113 |
|
|
2025
Q4 | $1.05M | Hold |
21,392
| – | – | 0.05% | 121 |
|
|
2025
Q3 | $923K | Hold |
21,392
| – | – | 0.04% | 128 |
|
|
2025
Q2 | $821K | Buy |
21,392
+3,000
| +16% | +$115K | 0.04% | 138 |
|
|
2025
Q1 | $713K | Buy |
18,392
+3,400
| +23% | +$124K | 0.03% | 137 |
|
|
2024
Q4 | $507K | Buy |
14,992
+2,500
| +20% | +$90K | 0.02% | 165 |
|
|
2024
Q3 | $511K | Buy |
12,492
+1,000
| +9% | +$40.9K | 0.02% | 173 |
|
|
2024
Q2 | $442K | Sell |
11,492
-1,500
| -12% | -$63.1K | 0.02% | 181 |
|
|
2024
Q1 | $557K | Buy |
12,992
+2,300
| +22% | +$94.8K | 0.02% | 153 |
|
|
2023
Q4 | $396K | Buy |
+10,692
| New | +$384K | 0.01% | 180 |
|
|
2022
Q3 | – | Sell |
-5,572
| Closed | -$303K | – | 260 |
|
|
2022
Q2 | $303K | Buy |
5,572
+404
| +8% | +$22.3K | 0.01% | 196 |
|
|
2022
Q1 | $281K | Sell |
5,168
-10
| -0.2% | -$543 | 0.01% | 226 |
|
|
2021
Q4 | $285K | Buy |
5,178
+4
| +0.1% | +$208 | 0.01% | 224 |
|
|
2021
Q3 | $247K | Buy |
5,174
+17
| +0.3% | +$854 | 0.01% | 222 |
|
|
2021
Q2 | $257K | Buy |
5,157
+5
| +0.1% | +$240 | 0.01% | 218 |
|
|
2021
Q1 | $230K | Buy |
5,152
+4
| +0.1% | +$182 | 0.01% | 227 |
|
|
2020
Q4 | $237K | Sell |
5,148
-376
| -7% | -$17.3K | 0.01% | 227 |
|
|
2020
Q3 | $260K | Buy |
5,524
+3
| +0.1% | +$150 | 0.01% | 195 |
|
|
2020
Q2 | $281K | Buy |
5,521
+4
| +0.1% | +$205 | 0.02% | 180 |
|
|
2020
Q1 | $261K | Buy |
5,517
+440
| +9% | +$23.5K | 0.02% | 184 |
|
|
2019
Q4 | $298K | Buy |
5,077
+1,167
| +30% | +$64.9K | 0.02% | 198 |
|
|
2019
Q3 | $209K | Buy |
+3,910
| New | +$201K | 0.01% | 227 |
|
|
2019
Q2 | – | Sell |
-4,805
| Closed | -$251K | – | 230 |
|
|
2019
Q1 | $251K | Sell |
4,805
-88
| -2% | -$4.4K | 0.02% | 175 |
|
|
2018
Q4 | $234K | Buy |
+4,893
| New | +$241K | 0.02% | 173 |
|
|
2014
Q4 | – | Sell |
-3,820
| Closed | -$220K | – | 295 |
|
|
2014
Q3 | $220K | Buy |
3,820
+11
| +0.3% | +$674 | 0.02% | 282 |
|
|
2014
Q2 | $255K | Buy |
3,809
+234
| +7% | +$15.8K | 0.03% | 273 |
|
|
2014
Q1 | $239K | Buy |
+3,575
| New | +$242K | 0.03% | 271 |
|
|
2013
Q4 | – | Sell |
-4,865
| Closed | -$305K | – | 304 |
|
|
2013
Q3 | $305K | Hold |
4,865
| – | – | 0.04% | 242 |
|
|
2013
Q2 | $303K | Buy |
+4,865
| New | +$309K | 0.04% | 239 |
|
Other funds holding GSK
JEST
Dearborn Partners's GSK Position: Q1 2026 in Review
Dearborn Partners held its GSK (GSK) position steady in Q1 2026 at 21,392 shares worth $1.18M. The position accounts for 0.06% of the portfolio, ranked #113.
Dearborn Partners first reported a position in GSK in Q2 2013 and has held it in 29 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Dearborn Partners held 21,392 shares of GSK worth $1.18M as of Q1 2026.
- Dearborn Partners left its GSK share count unchanged in Q1 2026.
- GSK made up 0.06% of Dearborn Partners's portfolio in Q1 2026, its #113 holding.
- Dearborn Partners first reported a position in GSK in Q2 2013 and has held it in 29 quarters since.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Dearborn Partners's 13F filing for Q1 2026, filed 12 May 2026.